CARsgen Therapeutics Holdings Limited (CARSGEN-B, 02171) disclosed its inclusion in the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect, effective March 9, 2026. According to the announcement, this development allows eligible mainland Chinese investors to directly trade the company's shares through respective stock exchanges.
The announcement highlights that this inclusion signals market recognition of CARSGEN-B’s CAR-T business potential and is expected to provide mainland investors with a more convenient investment channel while enhancing market attention and liquidity. The board of directors advises shareholders and potential investors to exercise caution when dealing in the shares.
Comments